Abstract Details

Title Vitamin D Deficiency and Its Relationship to Statin Intolerance among Stroke Patients

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) (-)

Poster/Presentation
Number 002

Objective

Background Statin therapy has been shown to be effective in secondary stroke prevention however muscle-related side effects can limit adherence to therapy. The vitamin D receptor is present in skeletal muscle and vitamin D deficiency can cause myopathy. There is limited data on the relationship of vitamin D deficiency to muscle-related side effects from statins.

Design/Methods We conducted retrospective chart review of stroke patients seen in The Emory Clinic from October 1, 2010 to December 31, 2011. All patients with documentation of statin use and serum 25-hydroxy vitamin D level were included in this analysis. Patient were categorized as vitamin D deficient if their levels were <30 ng/mL. Normal and vitamin D deficient groups were analyzed for their tolerance to statin. Baseline characteristics and tolerance to statin therapy were analyzed between normal and vitamin D deficiency group using Fishers Exact test.

Results Of 197 patients included in the study, 119 patients (60.4%) had vitamin D deficiency. Patients with deficiency were younger, more likely to be female and African American. Within the vitamin D deficient group, 14 (11.8%) did not tolerate any statin and 10 (8.4%) had muscle-related complant. Intolerance to multiple statins was more frequent in patients with vitamin D deficiency versus those with normal vitamin D (5.0% vs 0%; p=0.08).

Conclusions We found that vitamin D deficient stroke patients tended to have higher rates of intolerance to multiple statins compared with patients who had normal levels but this did not reach significance. A larger study is needed to better evaluate the relationship between statin intolerance and vitamin D deficiency.

Authors/Disclosures
Kumiko Owada, MD (Wellstar Medical Group) PRESENTER	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Fadi B. Nahab, MD	Dr. Nahab has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Legal Consultation. Dr. Nahab has received intellectual property interests from a discovery or technology relating to health care.
Aksel Siva, MD (Istanbul University Cerrahpasa School of Medicine)	Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi-Genzyme. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen - TR. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ali Raif Pharmaceuticals, Turkiye. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanovel Pharmaceuticals, Turkiye. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abdi Ibrahim Ilac - TR. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck Serono . The institution of Dr. Siva has received research support from Turkish MS Society. The institution of Dr. Siva has received research support from The Scientific and Technological Research Council Of Turkey - Health Sciences Research Grants.

��ɫ��

��ɫ��